Cargando…
A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy
BACKGROUND: Intravenous glucocorticoids (ivGC) have been recommended as a first-line treatment of moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). However, not all patients are responsive to ivGC. The identification of potential factors used to predict their efficacy and the se...
Autores principales: | Wang, Yang, Zhang, Shuo, Zhang, Yidan, Liu, Xingtong, Gu, Hao, Zhong, Sisi, Huang, Yazhuo, Fang, Sijie, Sun, Jing, Zhou, Huifang, Fan, Xianqun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819263/ https://www.ncbi.nlm.nih.gov/pubmed/29463244 http://dx.doi.org/10.1186/s12902-018-0240-8 |
Ejemplares similares
-
The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy
por: Huang, Yazhuo, et al.
Publicado: (2018) -
Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development
por: Huang, Yazhuo, et al.
Publicado: (2020) -
Bovine Acellular Dermal Matrix for Levator Lengthening in Thyroid-Related Upper-Eyelid Retraction
por: Sun, Jing, et al.
Publicado: (2018) -
Orbital radiotherapy plus three-wall orbital decompression in a patient with rare ocular manifestations of thyroid eye disease: case report
por: Zhang, Shuo, et al.
Publicado: (2018) -
Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients
por: Ahn, Hwa Young, et al.
Publicado: (2020)